Accelerate@Babraham has unveiled its 2025 cohort, selecting five pioneering life science ventures from a competitive pool of 37 applicants—marking a 50% surge in interest. Now in its seventh year, the accelerator at Babraham Research Campus continues to nurture early-stage innovation, having already supported 32 companies and helped raise over £100m.

This year’s cohort includes: AAB Research, developing EV-based cancer therapies; AmnioCam, offering a scalable stem cell-based solution for chronic wound care; Cycle Therapeutics, innovating endometriosis treatment via menstrual fluid analytics; MabGalaxy, using AI to expedite antibody drug discovery; and Sysora Health, tackling gum disease with precision antibacterial gels.

The programme offers an 8-week bespoke curriculum, lab space for a year, £10k funding, and access to a robust support network and facilities. Also joining are three Cambridge NeuroWorks Frontier Fellows via ARIA, aiming to fast-track neurotechnology development.

These ventures now embark on a journey designed to refine their commercial strategies and accelerate towards market readiness, supported by Babraham’s world-class ecosystem.